<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791035</url>
  </required_header>
  <id_info>
    <org_study_id>AMC 2016-0100</org_study_id>
    <nct_id>NCT02791035</nct_id>
  </id_info>
  <brief_title>Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the correlation between change of HbA1c, urinary
      glucose excretion and other factors when ipragliflozin is added to preexisting therapy in
      subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between change of HbA1c and urinary glucose excretion</measure>
    <time_frame>Baseline and week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between reduction in HbA1c and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between increase in urinary glucose excretion and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chang e of fasting glucose</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of waist circumference</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving the target HbA1c(&lt;6.5%)</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ipragliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral administration of Ipragliflozin</intervention_name>
    <arm_group_label>Ipragliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who has written informed consent

          -  Subjects who are diagnosed as type 2 diabetes mellitus

          -  Subjects who are 20 to 70 years old

          -  Subjects on a stable diet and exercise at least 8 weeks prior to the study
             participation

          -  Stable doses of the following medications for 8 weeks or more but, HbA1c level of 7.0
             to 9.5% (Metformin, Metformin + SU, Metformin + DPP-4 inhibitor, Metformin + TZD, TZD,
             TZD + SU, TZD + DPP-4 inhibitor, SU, SU + DPP-4 inhibitor, DPP-4 inhibitor)

        Exclusion Criteria:

          -  Type 1 DM

          -  Gestational DM

          -  Diabetic ketoacidosis

          -  CKD stage 3B-5 (eGFR 45)

          -  Severe infection, serious trauma, or perioperative period

          -  Known or suspected hypersensitivity to ipragliflozin

          -  Symptomatic urogenital infection

          -  Chemotherapy or radiation therapy for malignant tumor or diagnosis of malignant tumor
             within 5 years (except for thyroid cancer)

          -  Under the therapeutic intervention and/or another clinical study using IP drug

          -  Hepatic disease ( 3 times of upper normal limit of AST or ALT)

          -  Serious voiding difficulty due to neurogenic bladder or prostate hyperplasia

          -  Drugs not allowed for concomitant use

               -  Alpha glucosidase inhibitor or meglitinide within 60 days prior to screening

               -  Insulin within 60 days prior to screening

               -  Systemic steroid use (PO, IV or IM) over 2 weeks within 3 months prior to
                  screening

               -  Inhalation or pleural intracavitary injection of steroid known as having high
                  systemic absorption rate

          -  GLP-1 agonist (except for exenatide) within 60 days prior to screening

          -  Heart failure (NYHA class III-IV) or uncontrolled arrhythmia within 6 months prior to
             screening

          -  Cardiovascular diseases (unstable angina, myocardial infarction, transient ischemic
             attack, cerebrovascular disease, coronary artery bypass graft, or percutaneous
             coronary intervention) within 3 months prior to screening

          -  Subjects who are not eligible to the study according to an investigator's decision

          -  Inability to read the consent form

          -  Pregnancy, lactation, or plan to get pregnant during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>WOO JE LEE</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

